Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial ; volume:23 ; number:1 ; day:3 ; month:1 ; year:2023 ; pages:1-9 ; date:12.2023
BMC cancer ; 23, Heft 1 (3.1.2023), 1-9, 12.2023
- Creator
-
Miura, Satoru
Koh, Yasuhiro
Azuma, Koichi
Yoshioka, Hiroshige
Koyama, Kenichi
Teraoka, Shunsuke
Ishii, Hidenobu
Kibata, Kayoko
Ozawa, Yuichi
Tokito, Takaaki
Oyanagi, Jun
Shimokawa, Toshio
Kurata, Takayasu
Yamamoto, Nobuyuki
Tanaka, Hiroshi
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-022-10467-w
- URN
-
urn:nbn:de:101:1-2023031909015536074400
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:55 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Miura, Satoru
- Koh, Yasuhiro
- Azuma, Koichi
- Yoshioka, Hiroshige
- Koyama, Kenichi
- Teraoka, Shunsuke
- Ishii, Hidenobu
- Kibata, Kayoko
- Ozawa, Yuichi
- Tokito, Takaaki
- Oyanagi, Jun
- Shimokawa, Toshio
- Kurata, Takayasu
- Yamamoto, Nobuyuki
- Tanaka, Hiroshi
- SpringerLink (Online service)
Other Objects (12)
Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
Correction: Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
Successful osimertinib rechallenge in a patient with advanced non-small cell lung cancer following osimertinib-induced interstitial lung disease after treatment with nivolumab
Osimertinib in Indian patients with T790M-positive advanced nonsmall cell lung cancer
Successful Rechallenge with Osimertinib following Osimertinib-Induced Ventricular Tachycardia: A Case Report
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer
Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer
Elevated exosome-derived miRNAs predict osimertinib resistance in non-small cell lung cancer
Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis
Sunvozertinib overcoming resistance to afatinib and osimertinib in lung adenocarcinoma harboring an EGFR exon 18 DelE709_T710insD mutation
EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients
Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
Correction: Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
Successful osimertinib rechallenge in a patient with advanced non-small cell lung cancer following osimertinib-induced interstitial lung disease after treatment with nivolumab
Osimertinib in Indian patients with T790M-positive advanced nonsmall cell lung cancer
Successful Rechallenge with Osimertinib following Osimertinib-Induced Ventricular Tachycardia: A Case Report
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer
Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer
Elevated exosome-derived miRNAs predict osimertinib resistance in non-small cell lung cancer
Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis
Sunvozertinib overcoming resistance to afatinib and osimertinib in lung adenocarcinoma harboring an EGFR exon 18 DelE709_T710insD mutation
EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients
Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
Correction: Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
Successful osimertinib rechallenge in a patient with advanced non-small cell lung cancer following osimertinib-induced interstitial lung disease after treatment with nivolumab
Osimertinib in Indian patients with T790M-positive advanced nonsmall cell lung cancer
Successful Rechallenge with Osimertinib following Osimertinib-Induced Ventricular Tachycardia: A Case Report
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer
Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer
Elevated exosome-derived miRNAs predict osimertinib resistance in non-small cell lung cancer
Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis
Sunvozertinib overcoming resistance to afatinib and osimertinib in lung adenocarcinoma harboring an EGFR exon 18 DelE709_T710insD mutation